Video & Transcript Research : 'pharmaceutical expansion'
Page 22 of 392
MN
Minnesota 2025-2026 Regular Session
Committee on Health and Human Services - 03/11/25
Health and Human Services
Transcript Highlights:
- We stand ready to meet this urgent need, but we require state support to ensure this expansion is financially
- we require state support to ensure but we require state support to ensure this<00:09:54.720><c> expansion
- </c><00:09:55.200><c> is</c><00:09:55.440><c> financially</c><00:09:56.240><c> and</c> this expansion
- is financially and this expansion is financially and operationally operationally operationally sustainable
- Roundtable RX, you're ensuring that Minnesotans can access the medications they need, reducing pharmaceutical
TX
Texas 89th Regular
S/C on Disease Prevention & Women's & Children's Health Mar 27th, 2025
S/C on Disease Prevention & Women's & Children's Health
Transcript Highlights:
- House Bill 1782's expansion of Medicaid assistance for breast and cervical cancer treatment to those
- Telepharmacies can improve access to pharmaceutical services. for the elderly and disabled.
- I want to be clear: this isn't Medicaid expansion.
- This is not an expansion program; it's not changing the standards.
Keywords:
Medicaid, child health, express lane option, income verification, supplemental nutrition assistance, telepharmacy, healthcare access, remote dispensing, rural clinics, pharmacy regulations, health literacy, state health plan, health care, patient outcomes, public health, economic impact, healthcare, breast cancer, cervical cancer, insurance eligibility
MN
Transcript Highlights:
- colleagues said, quote, "This is the medical school that taught me I cannot accept a pen from a pharmaceutical
- from</c><00:14:57.280><c> a</c> me I cannot accept a pen from a me I cannot accept a pen from a pharmaceutical
- rep because it might pharmaceutical rep because it might impact<00:14:59.920><c> how</c><00:15:00.120
- Chair, between private equities Chair, between private equities expansion<00:27:29.920><c> into</c><00
- into the health care space and expansion into the health care space and now<00:27:32.160><c> insurance
MN
Minnesota 2025-2026 Regular Session
House Health Finance and Policy Committee 3/2/26
Health Finance and Policy
Transcript Highlights:
- when we're looking at the spectrum of mental health care, mental health, mental illness, uh, pharmaceutical
- I mean, it's so moving and to uh, pharmaceutical drugs that people are uh, pharmaceutical drugs that
- have not led show that these investments have not led to<01:10:55.840><c> an</c><01:10:56.080><c> expansion
- of</c><01:10:56.800><c> methadone</c><01:10:57.440><c> access</c><01:10:58.080><c> or</c> to an expansion
- of methadone access or to an expansion of methadone access or any<01:10:58.719><c> change</c><01:10:
Keywords:
gun violence, public health, Department of Health, prevention, criminal justice, health care transparency, ownership disclosure, control reporting, health care consolidation, private equity, management services organization, MSO, provider organization, health insurer, pharmacy benefit manager, hospital system, affiliate reporting, financial disclosure, public reporting, market concentration
HI
Hawaii 2026 Regular Session
CPN, CPN, CPN DEFER, CPN-JDC, HHS-CPN, CPN DEFER Public Hearings 02-17-2026
Transcript Highlights:
- Those are all important to make sure that the pharmaceutical sales are compliant and to verify that they're
- <c> sales</c><00:49:56.640><c> are</c><00:49:57.119><c> compliant</c><00:49:58.240><c> um</c> pharmaceutical
- sales are compliant um pharmaceutical sales are compliant um and<00:49:58.480><c> to</c><00:49:58.720
- Once this infrastructure is created, it's going to become the very foundation of future expansion and
- </c> of future expansion and industry growth. of future expansion and industry growth.
Summary:
The committee first heard SB 888, which would bar operators of smart household security devices from sharing user data with law enforcement unless the user consents or police obtain a warrant. DCCA’s Office of Consumer Protection offered comments and Judiciary submitted written support. Several individuals also submitted written support. The committee recommended passage with amendments clarifying that the Office of Consumer Protection may enforce violations and adopting Judiciary’s recommended changes, while also deferring the effective date to July 1, 2050. The motion passed unanimously among members present, with one senator excused.
The committee then took up SB 2777 on insurance disclosures. The bill would require authorized insurers to disclose claim-handling data to consumers, including claims open at the start of a period, closed with payment, closed without payment, and open at the end of the period. The committee described amendments to clarify the bill, remove a requirement for the DCCA insurance division to handle publication, and defer the effective date to July 1, 2050. The measure was passed with amendments and the recommendation was adopted, with one member voting no and another excused.
In a joint Commerce and Consumer Protection/Judiciary hearing on SP2738 relating to tax haven abuse, the Department of Taxation offered comments and the Tax Foundation testified in opposition, arguing the state should rely on IRS audits and existing worldwide reporting rules rather than create a separate state approach. Other written testimony was noted in both support and opposition. The committees recommended passage with amendments adopting Taxation’s technical changes and deferring the effective date to July 1, 2050; the recommendation was adopted, with one senator noting reservations.
The joint hearing then moved to health-related bills, including SB 2690 on primary care spending, SB 3103 on energy assistance, SB 3137 on Department of Health authority over food, drugs, and cosmetics, SB 3164 on child welfare service organizations, and SB 3206 on cannabinoids. SB 2690 drew strong support from physicians and advocates who said it would address primary care shortages, especially on neighbor islands, while HMSA and others warned a fixed spending percentage could raise costs and suggested a working group. SB 3164 drew support from child welfare providers and opposition from the Attorney General over indemnification language, and SB 3206 drew mixed testimony: state agencies raised federal-law and vagueness concerns, while hemp and cannabis advocates and some farmers supported the measure and urged broader legalization or amendments.
MN
Minnesota 2025-2026 Regular Session
'Parent's Bill of Rights' bill advances in House committee 2/12/25
Transcript Highlights:
- even more upsetting when you consider the rapid increase of school-based health clinics and the expansion
- increase of school-based health clinics increase of school-based health clinics and<00:10:19.200><c> expansion
- for</c><00:10:19.839><c> full</c><00:10:20.120><c> service</c><00:10:20.519><c> Community</c> and expansion
- for full service Community and expansion for full service Community Schools<00:10:21.279><c> across<
- <00:49:30.640><c> and</c><00:49:30.760><c> supplemental</c> pharmaceutical and supplemental pharmaceutical
MO
Missouri 2026 Regular Session
Joint Committee on Administrative Rules Jun 12th, 2026 at 10:00 am
Joint Committee on Administrative Rules
Transcript Highlights:
- And also, it doesn’t change the fact that the expansion is not just an expansion in name.
- And that's one of the concerns I have about this expansion is that we are going into professions that
- And the expansion in this rule contemplates that, yes, that is the case. So that's where we were.
- You have to prove hours of pharmaceutical training, be educated, and pay about $800 every five years
- This type of expansion should not be done in a rulemaking process.
Summary:
The Joint Committee on Administrative Rules met to consider Missouri PDMP rule 1 CSR 60-1.010 after the Department of Natural Resources withdrew its unrelated proposals. The hearing focused on a proposed expansion of access to the Prescription Drug Monitoring Program for additional behavioral health professionals, including licensed clinical social workers, licensed master social workers, marital and family therapists, professional counselors, and psychologists, along with related clarifications to delegate access. Supporters from the PDMP task force, Compass Health, and the Department of Mental Health argued the change would improve care coordination, medication reconciliation, and safety in multidisciplinary behavioral health settings, especially CCBHCs, and cited federal expectations that PDMPs be consulted in care planning. They also said access would remain limited to licensed Missouri professionals working under supervision or collaboration with prescribers or dispensers, and that misuse could be sanctioned.
Committee members raised concerns about statutory authority, privacy, and whether the rule would substantially expand access beyond what the original PDMP legislation contemplated. Several members questioned whether the change should be made by statute rather than rule, whether it could be used for non-treatment purposes such as custody disputes, and whether the expansion would alter the character of the program. A chronic pain patient testified in opposition, warning that broader access could discourage patients from seeking counseling and could further burden people already affected by controlled-substance monitoring and prescribing restrictions.
After public testimony, the committee debated the legality of the rule rather than its policy merits. A motion was made to disapprove the rule under RSMo 536.014 for lack of statutory authority, conflict with state law, and being arbitrary and capricious. The motion was supported by several members who said the change should go through the legislative process; one member opposed, arguing the rule was a practical extension of existing authority. On a roll call vote, the committee voted 7-1 to disapprove Rule 1 CSR 60-1.010, and the meeting adjourned.
MN
Minnesota 2025-2026 Regular Session
FULL INTERVIEW: Patient-Centered Care | Senator John Marty Mar 20th, 2026
Minnesota Senate Floor Meeting
Transcript Highlights:
- Same thing pharmaceutical industry, we need the pharmaceuticals, but we don't need to pay exorbitant
- Same thing pharmaceutical industry, we need the pharmaceuticals, but we don't need to pay exorbitant
- Same thing pharmaceutical industry, we need the pharmaceuticals, but we don't need to pay exorbitant
- Same thing pharmaceutical industry, we need the pharmaceuticals, but we don't need to pay exorbitant
- Same thing pharmaceutical industry, we need the pharmaceuticals, but we don't need to pay exorbitant
Summary:
The interview focused on Senate File 3612, which the senator described as “patient-centered care” legislation for Minnesota’s Medicaid and MinnesotaCare programs. He said the bill would remove private insurers and HMOs from administering those public programs, replace them with a state contract for claims processing and administrative services, and shift care coordination directly to primary care clinics, counties, and nonprofits. He argued the current managed-care system creates churn, prior-authorization barriers, and fragmented care, and said providers should manage care rather than insurers.
The senator repeatedly cited Connecticut as a model, saying that state moved away from managed care, improved primary care participation, and saved money. He also argued Minnesota’s current system lacks transparency and may be overpaying health plans, pointing to fraud concerns and a past example in which UCare returned money to the state after an overpayment. He said the bill would improve accountability, make fraud easier to detect, and could save taxpayers billions, though he emphasized his main goal was better care rather than savings.
On support and prospects, he said the bill has backing from the governor and the American Cancer Society but currently only DFL co-authors. He said he does not expect it to become law this year because the fiscal note and details are still pending, and he does not expect insurance companies to support it. He added that he is open to discussion but sees the insurers as fundamentally opposed. The interview ended with him saying workers in insurance and claims processing should be treated fairly and offered retraining or dislocated-worker support if broader reforms reduce their roles.
CA
California 2025-2026 Regular Session
Assembly Health Committee Mar 24th, 2026
Transcript Highlights:
- Dietary supplements are not regulated like pharmaceutical drugs.
- Dietary supplements are not regulated like pharmaceutical drugs.
- Yet over the last decade, more than 750 supplement brands have been found to be tainted with pharmaceutical
- enrollment periods are limited to broad qualifying life events, such as marriage, relocation, family expansion
Summary:
The Assembly Health Committee heard several bills focused on workforce access, consumer protection, behavioral health parity, and public health safety. AB 1591 by Assembly Member Michelle Rodriguez would create a podiatric medicine pipeline program to address shortages of podiatrists, especially in rural and underserved counties; it drew strong support from podiatrists and medical groups and no opposition. AB 2011 by Assembly Member Hart would codify federal mental health and substance use disorder parity standards into state law; supporters argued it would preserve access if federal enforcement weakens, while health plans and insurers opposed it as premature and potentially confusing. The bill was moved on a due pass motion to Appropriations and remained on call after a roll vote with several ayes and some noes.
The committee also considered AB 2311 by Assembly Member Chiavo, which would allow public health care district hospitals to directly employ physicians. Supporters said the change would help district hospitals recruit and retain doctors and stabilize care in underserved communities, while CMA and emergency physicians warned it could weaken the corporate practice of medicine protections and physician autonomy. Members raised concerns about guardrails, but the author said the bill would continue to be refined; it passed on a due pass motion to the Business and Professions Committee. AB 2030 by Assembly Member Lowenthal would prohibit sales of over-the-counter diet pills and weight-loss or muscle-building supplements to minors, with supporters citing eating disorder risks and opponents objecting to scope, age-verification, and retail requirements. The bill passed on a due pass motion to the Judiciary Committee.
AB 1864 by Assembly Member Berman would require screening of gene synthesis orders to prevent misuse for bioterrorism and would authorize enforcement penalties for noncompliance. Supporters from Stanford, Encode, and the medical community said the measure would align California with federal best practices and address growing biosecurity risks, while life sciences representatives raised concerns about operational burdens and supply-chain impacts. Members discussed whether the bill should include an urgency clause and how to keep the standards current; it passed to the Judiciary Committee. AB 2457 by Assembly Member Connolly would standardize and speed up Medi-Cal managed care credentialing for physicians, and it passed to Appropriations with broad support. Finally, AB 2302, presented on behalf of Assembly Member Celeste Rodriguez, would require infant formula manufacturers to test for toxic elements such as lead and arsenic and post results publicly; pediatric and disability advocates supported the measure as a transparency and infant safety bill.
CA
Transcript Highlights:
- Dietary supplements are not regulated like pharmaceutical drugs.
- Dietary supplements are not regulated like pharmaceutical drugs.
- Yet over the last decade, more than 750 supplement brands have been found to be tainted with pharmaceutical
- enrollment periods are limited to broad qualifying life events, such as marriage, relocation, family expansion
CO
Colorado 2026 Regular Session
Colorado House 2026 Legislative Day 086 Part 2 Apr 10th, 2026
Colorado House Floor Meeting
Transcript Highlights:
- This has been explosive and exponential in expansion.
- This has been explosive and exponential in expansion.
- We do not know what this in expansion.
- ,</c><03:40:11.200><c> hepatitis</c><03:40:11.680><c> C</c> purchase of pharmaceuticals, hepatitis C
- </c><05:36:27.760><c> fund</c> be from the healthcare expansion fund be from the healthcare expansion
MA
Massachusetts 2025-2026 Regular Session
Public Health Effects of Xylazine Jun 21st, 2026 at 02:00 pm
Transcript Highlights:
- I don't know if we'll touch on this, but pharmaceutical-grade xylazine versus non-pharmaceutical-grade
- compounds that you would attain from a pharmacy or from a pharmaceutical distributor or a compounding
- The non-PG, as we call non-pharmaceutical-grade compounds.
- It's a difference between, you know, pharmaceutical-grade approved versus, you know, what's out there
- fentanyl and the non-pharmaceutical-grade fentanyl or the non-controlled production fentanyl.
Summary:
The working group on best practices for oversight and enforcement met for its first session and focused on xylazine, including its legal veterinary uses, its appearance in the illicit drug supply, and whether it should be classified as a controlled substance. Members discussed the distinction between pharmaceutical-grade and non-pharmaceutical-grade xylazine, the role of international/illicit sourcing, and the limits of state-level regulation if the substance is already being added to fentanyl or other drugs outside the Commonwealth. The Department of Public Health representative summarized the agency’s view that scheduling xylazine could follow the “ironclad law of prohibition” and push the market toward other, potentially worse substances, and said DPH opposed straight scheduling in favor of education, support, and harm-reduction approaches.
Veterinary members explained how xylazine is used in large-animal and research settings, why it is useful, and why federal-style scheduling could create practical burdens for veterinarians who work in the field. They also described reversal agents such as yohimbine and atipamezole (Antisedan), and noted that xylazine is not commonly used in small-animal practice. Several members raised questions about how much xylazine is actually used legally in Massachusetts, whether boards of pharmacy or distributors could provide useful data, and what other states have done. Arizona and Florida were mentioned as possible examples for further research, along with the need to examine stakeholder opposition and any effects on legitimate veterinary practice.
The group agreed to divide into two subgroups: one focused on oversight and regulation of production/distribution, and another on whether xylazine should be classified as a controlled substance and what penalties, if any, should apply. Staff said they would circulate notes, a draft PowerPoint template, and a shared folder, with members asked to submit materials by December 2, draft materials due December 4, and final approval by December 9 ahead of the next public meeting on December 11. The meeting ended with a motion to adjourn, a second, and unanimous closure.
MO
Missouri 2026 Regular Session
Higher Education and Workforce Development Feb 10th, 2026
Higher Education and Workforce Development
Transcript Highlights:
- Currently, most active pharmaceutical ingredients, APIs, are manufactured in China and India.
- This would support broader pharmaceutical sector growth, technological advancement, and assist in efforts
- That's the industry I came from, and I used to deal with all these CEOs of these large pharmaceutical
- And, you know, I keep hearing that New Jersey gets a lot of the medical, the pharmaceutical companies
- And you're in pharmaceuticals. Okay, just real quick, then, you're in pharmaceuticals.
Summary:
The committee first heard House Bill 2896, sponsored by Rep. Brown, which would change how boards of governors for state universities are selected. Brown said the bill, developed with input from the governor’s office, would simplify appointment rules by removing service-area and congressional-district requirements and instead limiting board membership so no more than half of the voting members come from the county where the institution is located, with a St. Louis exception. Members asked about Missouri residency requirements, the effect on Missouri State University and Southeast Missouri State University, and whether university presidents would recommend candidates to the governor. Brown said he would follow up on questions and was open to discussing possible adjustments, especially regarding geographic representation. One witness spoke in favor, arguing that boards should reflect a cross-section of the state. No opposition was presented, and the hearing on HB 2896 was closed.
The committee then took up House Bill 1659, the Missouri Defense and Energy Independence Act, sponsored by Rep. Steinmeyer. The bill would create a grant program to help Missouri manufacturers convert facilities to produce strategic materials tied to national defense and energy resilience. Steinmeyer described it as a private-capital-first program requiring at least $500,000 in private investment, with grants capped at $1 million per project per year, subject to appropriation, annual reporting, and repayment provisions if projects fail. He said the bill is intended to attract investment, create jobs, and strengthen supply chains while keeping taxpayer risk limited.
Members raised concerns about environmental and public safety risks, the bill’s placement in the higher education committee, whether it should instead be funded federally, and whether the program would mainly benefit large companies rather than small businesses. Questions also focused on the bill’s workforce-development component, the lack of detail on training and public-health protections, and the budget impact of creating a dedicated fund that would retain money and interest rather than sweep it to general revenue. Steinmeyer said the bill is meant to support existing Missouri companies or companies establishing headquarters in Missouri, and that universities had been involved in discussions about workforce needs. A representative from the API Innovation Center testified in favor, saying the bill could help develop key starting materials for pharmaceuticals and support reshoring. One witness testified in opposition, arguing the state should not subsidize private industry and warning about fiscal strain and environmental oversight. No vote was taken, and the hearing concluded without further action.
FL
Florida 2026 Regular Session
Senate in Special Session E May 29th, 2026
Florida Senate Floor Meeting
Transcript Highlights:
- Development Capitalization Incentive Grant Program for public schools and colleges to fund the creation or expansion
- In addition, anticipated pharmaceutical cost overruns... ...in a stronger financial position moving forward
- In addition, anticipated pharmaceutical cost overruns have been avoided through a department initiative
- And so we have funded three additional expansions of state parks.
- To the contrary, because Florida was not an expansion state, we will not feel the impacts of what other
Summary:
The Senate convened with prayer and the Pledge of Allegiance, then moved to the conference report on House Bill 501E, the General Appropriations Act for fiscal year 2026-27. Budget chairs presented the major spending areas, describing a $114.5 billion overall budget that they said was fiscally responsible and below the prior year’s spending. Highlights included pay increases and retirement adjustments for public safety employees, education funding for K-12, higher education, health and human services, criminal justice, transportation, environmental programs, and agriculture/regulatory agencies.
Members then questioned chairs on several items. In education, senators discussed K-12 declining enrollment funding, teacher salary set-asides, private school scholarship spending, mental health funding, preeminence funding for universities, the Hamilton Center at UF, and charter school PICO funding. In health and human services, questions focused on the iBudget waiver waitlist, provider rates, ADAP/HIV funding and the return of Biktarvy to the formulary, KidCare, rural health funding, SNAP-related IT and error reduction efforts, and the IDD managed care program. In criminal justice, senators asked about correctional officer pay, prison staffing and infrastructure, air conditioning in prisons, juvenile justice facilities, law enforcement recruitment, and court system funding. Environmental and transportation questions covered Florida Forever, water quality, state parks, water projects, housing, elections funding, and emergency management.
Several specific actions and explanations were given during debate: the budget includes $8.8 million for state attorney competitive area differentials but no funding for public defender CAD requests; assistant state attorneys will start at $70,000 and assistant public defenders at $65,000; the battery disposal issue was described as a temporary study/preemption approach; and the Senate said the budget does not fund Medicaid expansion, preeminence funding, or the SunBucks Summer EBT state share. Senators also noted that some proposals discussed in committee did not make it into the final budget. The transcript ends with debate statements from members praising the budget process and Chair Hooper, while also expressing concerns about public schools, health care access, affordability, and the lack of funding for certain priorities.
MO
Missouri 2026 Regular Session
Higher Education and Workforce Development Feb 10th, 2026
Higher Education and Workforce Development
Transcript Highlights:
- Currently, most active pharmaceutical ingredients, APIs, are manufactured in China and India.
- And I used to deal with all these CEOs of these large pharmaceutical companies.
- Okay, just real quick then, you're in pharmaceuticals. Just help me connect the dots.
- They're already doing some pharmaceuticals that are generic, so anyway.
- They're already doing some pharmaceuticals that are generic, so anyway.
Summary:
The committee first heard House Bill 2896, sponsored by Rep. Brown, which would change how governing boards for state universities are selected. The bill would remove service-area and congressional-district requirements and instead limit board membership so no more than half of the voting members could reside in the county where the institution is located, with a St. Louis-specific exception. Brown said the goal was to broaden the pool of qualified appointees and make it easier for the governor to fill seats. Members asked about residency requirements, the loss of regional representation, and whether the Missouri State University board should still reflect statewide interests. One witness testified in support, saying boards should include a cross-section of the state. The hearing closed with no opposition testimony.
The committee then heard House Bill 1659, sponsored by Rep. Steinmeyer, which would create the Missouri Defense and Energy Independence Act to help Missouri manufacturers convert facilities to produce strategic materials tied to national defense and energy resilience. The bill would require at least $500,000 in private investment before a company could qualify, cap grants at $1 million per project per year, require appropriations, and include repayment provisions and a sunset. Steinmeyer said the bill is intended to attract investment, create jobs, and position Missouri in strategic supply chains while protecting taxpayers through caps and clawbacks. Supporters included the API Innovation Center, which said the bill could help develop key starting materials for pharmaceuticals and support reshoring of drug production.
Members raised substantial concerns about environmental and public safety risks, the bill’s fit in the higher education committee, whether it should instead be handled by economic development or federal entities, and whether the program would favor large companies over small businesses. Questions also focused on budget impacts, the proposed fund structure, and whether the bill should include stronger workforce, health, and environmental protections. The sponsor said the bill is meant to leverage existing Missouri facilities and workforce partnerships, and that state investment would help position Missouri for federal funding and future industry growth. One witness opposed the bill, arguing the private sector should bear the costs, warning about state budget pressures, and criticizing the creation of a new program and staff. No vote was taken in the transcript, and the committee concluded the hearing after testimony.
MN
Minnesota 2025-2026 Regular Session
House Floor Session 5/17/26 - Part 6
Minnesota House Floor Meeting
Transcript Highlights:
- It would encourage more pharmaceutical companies to cut their discounts.
- It would encourage<00:54:48.720><c> more</c><00:54:49.040><c> pharmaceutical</c><00:54:49.760><c> companies
- </c> encourage more pharmaceutical companies encourage more pharmaceutical companies to<00:54:50.480>
- <01:29:47.199><c> manufacturers</c><01:29:48.560><c> are</c><01:29:48.880><c> too</c> pharmaceutical
- manufacturers are too pharmaceutical manufacturers are too often<01:29:50.000><c> writing</c><01:29:50.320
KY
Kentucky 2026 Regular Session
Government Contract Review Committee (1-13-26) - Upon Adjournment
Transcript Highlights:
- </c> Thus, with the decreased enrollment, we are concerned about the expansion of dollars.
- He continued that there has been a dramatic increase in some litigation around the pharmaceutical space
- He said there has been a dramatic increase in some litigation around the pharmaceutical space, but he
- The 340B and these pharmaceutical things are extraordinarily complex.
- </c> as a result of the pharmaceutical as a result of the pharmaceutical companies<01:19:20.080><c> withholding
Keywords:
This meeting will take place Upon Adjournment of both Chambers. An exact time is not given or known at this time., 958, all
Summary:
The Government Contracts Committee met for its first 2026 meeting, approved the December 9 minutes, and reviewed 337 contracts totaling about $71.8 million. After a motion to consider the routine contract lists without objection passed, the committee pulled several items for discussion, including contracts from the Council on Postsecondary Education, the Department of Highways, the Kentucky Horse Racing and Gaming Commission, and Kentucky State University. Most items were ultimately approved by roll call votes.
For the Council on Postsecondary Education item, members discussed why the contract was not handled through the usual Finance Cabinet bidding process. Staff explained it stemmed from House Bill 200 and the healthcare workforce incentive fund, which uses a separate competitive award process and steering committee under different statutory standards. The committee accepted that explanation and approved the contract. Department of Highways staff then explained the difference between scour assessments, which evaluate erosion and foundation risk around bridge piers, and load ratings, which assess the bridge structure itself. Members also questioned a larger engineering contract increase; staff said it reflected progression from preliminary engineering to final design on a phased project and estimated the funding split at roughly 80% federal and 20% state. Those highway contracts were approved.
The Kentucky Horse Racing and Gaming Commission presented a legal services contract. Officials said the new corporation had identified legal needs, issued an RFP, and awarded four firms to create a pool of counsel to avoid conflicts as the agency now licenses racing, sports betting, and charitable gaming. They also said an emergency contract was needed after a temporary restraining order was issued in litigation involving charitable gaming machines and alleged losses to charities. The committee asked about the litigation and the affected organizations, and the contract was approved. Kentucky State University then defended a marketing/enrollment contract despite financial concerns, saying the work was intended to raise awareness of the university, improve enrollment, and support financial stability. University officials also said they were tightening student payment enforcement and collection practices, including payment plans and holding students accountable for balances. That contract was also approved.
MN
Minnesota 2025-2026 Regular Session
House Higher Education Finance and Policy Committee 1/21/25
Higher Education Finance and Policy
Transcript Highlights:
- We are looking into expansion to St. Cloud for a potential sixth campus.
- 00:03:34.959><c> are</c><00:03:35.120><c> looking</c><00:03:35.400><c> into</c><00:03:36.159><c> expansion
- </c> campuses we are looking into expansion campuses we are looking into expansion to<00:03:37.040><c
- Are we talking about also in our air and our water, all of these pharmaceuticals that land in our water
- that land in our water Pharmaceuticals that land in our water in<00:18:52.840><c> particular</c><00:
NM
New Mexico 2026 Regular Session
House - Commerce and Economic Development Jan 28th, 2026 at 02:54 pm
House Commerce & Economic Development Committee
Transcript Highlights:
- Second, with the IRB expansion...
- Second, with the IRB expansion, there was some concern about data centers, and I want to be clear that
- companies, by turning that tax credit into real cash flow that they can use for hiring, equipment, and expansion
- going to start doing everything, from infrastructure to, you know, power development to mixing pharmaceuticals
FL
Florida 2025 Regular Session
March 11, 2025 - 08:00 AM
Transcript Highlights:
- So it is important that other programs, such as the kid care expansion, and we don't often have good
- So it is important that other programs, such as the kid care expansion, and That other programs, such
- as the Kid Care expansion, and the option to treat the medically fragile child as a household of one
- My entire paycheck was going toward her medical bills, the supplies that she needed, the pharmaceutical
Summary:
The Health Care Facilities and Systems Subcommittee met with a quorum present and took up five bills. The first, CS/HB 1119 on pediatric readiness in hospital emergency departments, would require hospitals with ERs to adopt evidence-based pediatric care policies, train staff, designate a pediatric emergency care coordinator, complete the National Pediatric Readiness Assessment, and meet minimum equipment and planning standards. Members discussed transport to the closest appropriate facility and implementation concerns, but the bill passed 16-0.
The committee then approved HB 677, which would add standard fertility preservation services to the state group insurance program for employees undergoing chemotherapy, and CSHB 497, which would authorize nonprofit agricultural organization medical benefit plans for Florida Farm Bureau members, aimed at improving affordable coverage for farmers and ranchers. HB 677 passed 16-0, and CSHB 497 passed 18-0 after questions about membership, regulation, disclosures, and how the plan would compare with ACA coverage.
The subcommittee also approved PCS/HB 791 on surrendered newborn infants, allowing infant safety devices at hospitals, EMS stations, and fire stations as an alternative safe-haven option. Members discussed alarms, unmanned stations, and whether churches should be included; the bill passed 18-0. Finally, HB 1529 on home health aides for medically fragile children was amended and passed 18-0. The bill seeks a federal waiver so compensation for parents serving as home health aides does not count against Medicaid eligibility, and the amendments added reporting of adverse incidents, set work-hour limits, and protected certain other benefits. The chair closed by emphasizing the committee’s role in implementation oversight and fixing problems after enactment.